biostudies-literatureUnknown39(4)Mirioglu SThe histopathological lesions, minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are entities without immune complex deposits which can cause podocyte injury, thus are frequently grouped under the umbrella of podocytopathies. Whether MCD and FSGS may represent a spectrum of the same disease remains a matter of conjecture. Both frequently require repeated high-dose glucocorticoid therapy with alternative immunosuppressive treatments reserved for relapsing or resistant cases and response rates are variable. There is an unmet need to identify patients who should receive immunosuppressive therapies as opposed to those who would benefit from supportive strategies. Therapeutic trials focusing on MCD are scarce, and the evidence used for the 2021 Kidney Disease: ImprovingNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association569-580https://www.ebi.ac.uk/biostudies/studies/S-EPMC11024823biostudies-literatureManagement of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.PMC11024823Mirioglu SStevens KIBajema IMGoumenos DTurkmen KKronbichler AFrangou EAhmad SHFernandez-Juarez GMGriffith MSteiger SFloege Jvan Kooten CMoran SMWillcocks LCDaniel-Fischer LBerke IBruchfeld AfalseManagement of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.The histopathological lesions, minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are entities without immune complex deposits which can cause podocyte injury, thus are frequently grouped under the umbrella of podocytopathies. Whether MCD and FSGS may represent a spectrum of the same disease remains a matter of conjecture. Both frequently require repeated high-dose glucocorticoid therapy with alternative immunosuppressive treatments reserved for relapsing or resistant cases and response rates are variable. There is an unmet need to identify patients who should receive immunosuppressive therapies as opposed to those who would benefit from supportive strategies. Therapeutic trials focusing on MCD are scarce, and the evidence used for the 2021 Kidney Disease: Improving2024-01-01T00:00:00Z2024 Mar2026-05-29T17:46:01.118Z2025-07-27T03:10:30.073ZS-EPMC110248233834127610.1093/ndt/gfae025